Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
4.
JAMA Dermatol ; 151(12): 1365-1366, 2015 Dec 01.
Article in English | MEDLINE | ID: mdl-26465355
5.
Pediatr Dermatol ; 26(5): 636-8, 2009.
Article in English | MEDLINE | ID: mdl-19840338

ABSTRACT

We report a case of AFH presenting as an asymptomatic subcutaneous nodule on the arm of a 6-year-old boy. AFH is a fibrohistiocytic tumor of intermediate malignancy. Predominantly seen in children and young adults, AFH presents as a deep dermal or subcutaneous nodule usually on the extremities. The histology is characterized by a fibrous capsule, surrounding lymphocytic infiltrate and blood-filled cystic spaces lined by flattened tumor cells. AFH cells express desmin, epithelial membrane antigen, and CD 68 in over 60% of cases; they are negative for myogenin, MYOD1, and endothelial markers. Rate of local recurrence is 2% to 20%. The metastatic rate is 1%. Management is with wide surgical excision and careful follow-up.


Subject(s)
Hemangioma/pathology , Histiocytoma, Malignant Fibrous/pathology , Skin Neoplasms/pathology , Biopsy , Child , Hemangioma/surgery , Histiocytoma, Malignant Fibrous/surgery , Humans , Male , Skin Neoplasms/surgery
8.
Arch Intern Med ; 168(11): 1137-44, 2008 Jun 09.
Article in English | MEDLINE | ID: mdl-18541820

ABSTRACT

Genital and labial herpes simplex virus infections are frequently encountered by primary care physicians in the United States. Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research; (3) approved regimens of the Food and Drug Administration that may not match recommendations of the Centers for Disease Control and Prevention or of other experts; and (4) dissimilar regimens for oral and genital infections. The physician must first choose an approach to treatment (ie, intermittent episodic therapy, intermittent suppressive therapy, or chronic suppressive therapy) based on defined clinical characteristics and patient preference. Then, an evidence-based dosing regimen must be selected. In this review, data from all sources are tabulated to provide a handy clinical reference.


Subject(s)
Antiviral Agents/therapeutic use , Herpes Genitalis/drug therapy , Herpes Labialis/drug therapy , 2-Aminopurine/analogs & derivatives , 2-Aminopurine/therapeutic use , Acyclovir/analogs & derivatives , Acyclovir/therapeutic use , Drug Resistance, Viral , Evidence-Based Medicine , Famciclovir , Humans , Recurrence , Risk Factors , Valacyclovir , Valine/analogs & derivatives , Valine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL